Arbutus Biopharma Corporation: updates and filings

ABUSNASDAQHealthcare · Pharmaceutical Preparations

Price

$4.02

November 20, 2026Market cap $799M

What Ploutos Investor adds for Arbutus Biopharma

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • Profit over the last twelve months is well above what the business itself earned, because it includes large gains outside the business, such as on investments or from selling a business. The P/E is lower than the business alone would give.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 82 daysAround Feb 12, 2027 · for Q4 2026

last Nov 10, 2026next Feb 12, 2027

An estimate from when it has reported before, which has been regular. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 23, 2026 latest annualNov 10, 2026 latest quarterly
  • Nov 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 16, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Nov 12, 2026Other material events
    Form8-K
  • Nov 10, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Nov 10, 2026Results of operations
    Form8-K
  • Oct 27, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Oct 22, 2026Other material events
    Form8-K
  • Oct 7, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Oct 5, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Oct 1, 2026Filing (amendment)
    FormSC TO-I/A
  • Sep 30, 2026Filing (amendment)
    FormSC TO-I/A
  • Sep 4, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Aug 24, 2026Filing
    FormSC TO-I
  • Aug 21, 2026Filing
    FormSC TO-C
  • Aug 21, 2026Other material events
    Form8-K
  • Aug 12, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 12, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 12, 2026Results of operations
    Form8-K
  • Jul 16, 2026Material agreement ended, officer or director change, other material events
    Form8-K
  • Jun 5, 2026Shares registered for employees
    FormS-8
  • May 27, 2026Officer or director change, shareholder vote
    Form8-K
  • May 15, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 13, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • May 13, 2026Results of operations
    Form8-K

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Sep 30, 2008.

The full analysis

What do Arbutus Biopharma's filings show?

The filings are where every one of Arbutus Biopharma's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.